Double blood thinner strategy after vein stenting aims to prevent Re-Clotting

NCT ID NCT04694248

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking a blood thinner (rivaroxaban) plus aspirin after a vein-stenting procedure keeps the vein open longer and prevents new clots. About 172 people with deep vein thrombosis and narrowed iliac veins will receive the combination for 6 months (rivaroxaban) and indefinitely (aspirin). The main goal is to see if the vein stays open at 12 months without causing major bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rivaroxaban and Aspirin
What this could lead to: If successful, this could point to a safer, more effective way to prevent vein re-clotting after stenting, reducing long-term complications like post-thrombotic syndrome.
What could go wrong: This is a moderate-sized, early-stage trial (172 participants) with no placebo control. The main risk is increased bleeding from combining two blood thinners, and results may not apply to all DVT patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEEP VEIN THROMBOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

iliac vein thrombophlebitis May-Thurner syndrome venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEEP VEIN THROMBOSIS ILIAC VEIN COMPRESSION SYNDROME ILIAC VEIN OBSTRUCTION ILIAC VEIN STENOSIS ILIAC VEIN THROMBOSIS

Contacts and locations

Locations

The First Affliated Hospital, Zhejiang University, School of Medicine
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.